



# SAFETY DATA SHEET

Revision date: 13-Feb-2017

Version: 2.0

Page 1 of 8

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Metaxalone Tablets

**Trade Name:** SKELAXIN

**Chemical Family:** Not determined

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product

### Details of the Supplier of the Safety Data Sheet

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

**Emergency telephone number:**  
**CHEMTREC (24 hours): 1-800-424-9300**  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours): +1-703-527-3887**

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Acute Oral Toxicity: Category 4

### Label Elements

**Signal Word:** Warning  
**Hazard Statements:** H302 - Harmful if swallowed

**Precautionary Statements:** P264 - Wash hands thoroughly after handling  
P270 - Do not eat, drink or smoke when using this product  
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell  
P330 - Rinse mouth  
P501 - Dispose of contents/container in accordance with all local and national regulations



## SAFETY DATA SHEET

Material Name: Metaxalone Tablets  
Revision date: 13-Feb-2017

Page 2 of 8  
Version: 2.0

**Other Hazards** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

**Note:** This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Metaxalone	1665-48-1	216-777-6	Acute Tox. 4, H302	86.5
Magnesium Stearate	557-04-0	209-150-3	Not Listed	*
Starch	9005-25-8	232-679-6	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Alginate acid	9005-32-7	232-680-1	Not Listed	*
Ammonium alginate	9005-34-9	Not Listed	Not Listed	*
Calcium alginate	9005-35-0	Not Listed	Not Listed	*
Carmine (B Rose Liquid)	1390-65-4	215-724-4	Not Listed	*

**Additional Information:** \* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.  
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

#### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## SAFETY DATA SHEET

Material Name: Metaxalone Tablets  
Revision date: 13-Feb-2017

Page 3 of 8  
Version: 2.0

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

**Special Hazards Arising from the Substance or Mixture**

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Advice for Fire-Fighters**

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

**Personal Precautions, Protective Equipment and Emergency Procedures**

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Methods and Material for Containment and Cleaning Up**

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**Precautions for Safe Handling**

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Conditions for Safe Storage, Including any Incompatibilities**

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

**Magnesium Stearate**

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>
Sweden OEL - TWAs	5 mg/m <sup>3</sup>

**Starch**

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>

## SAFETY DATA SHEET

Material Name: Metaxalone Tablets  
Revision date: 13-Feb-2017

Page 4 of 8  
Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	4.0 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Slovakia OEL - TWA	4 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Switzerland OEL -TWAs	3 mg/m <sup>3</sup>

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

#### Metaxalone

**Pfizer Occupational Exposure Band (OEB):** OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

##### Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

##### Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

##### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

##### Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Tablets	<b>Color:</b>	Pink
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture
<b>Solvent Solubility:</b>	No data available		
<b>Water Solubility:</b>	No data available		

## SAFETY DATA SHEET

Material Name: Metaxalone Tablets  
Revision date: 13-Feb-2017

Page 5 of 8  
Version: 2.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

pH: No data available.  
Melting/Freezing Point (°C): No data available  
Boiling Point (°C): No data available.  
Partition Coefficient: (Method, pH, Endpoint, Value)

#### Alginate acid

No data available

#### Magnesium Stearate

No data available

#### Metaxalone

No data available

#### Starch

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

#### Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

### 10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

#### Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: See 'Known clinical effects', below.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including dizziness, drowsiness, muscle weakness, gastrointestinal disturbances, liver effects, and hypersensitivity reactions.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Alginate acid

Rat Oral LD 50 >5 gm/kg

## SAFETY DATA SHEET

Material Name: Metaxalone Tablets  
Revision date: 13-Feb-2017

Page 6 of 8  
Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

#### Metaxalone

Rat Oral LD50 775 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Metaxalone

Reproductive & Fertility Rat No route specified Dose not specified Not teratogenic, Negative

**Carcinogen Status:** Not listed as a carcinogen by IARC, NTP or US OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## SAFETY DATA SHEET

Material Name: Metaxalone Tablets  
Revision date: 13-Feb-2017

Page 7 of 8  
Version: 2.0

### 15. REGULATORY INFORMATION

#### Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

##### Alginic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-680-1

##### Ammonium alginate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

##### Calcium alginate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

##### Metaxalone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	216-777-6

##### Carmine (B Rose Liquid)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	215-724-4

##### Magnesium Stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

##### Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

## SAFETY DATA SHEET

Material Name: Metaxalone Tablets  
Revision date: 13-Feb-2017

Page 8 of 8  
Version: 2.0

### 15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

<b>Data Sources:</b>	Publicly available toxicity information. Safety data sheets for individual ingredients.
<b>Reasons for Revision:</b>	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection.
<b>Revision date:</b>	13-Feb-2017 Product Stewardship Hazard Communication
<b>Prepared by:</b>	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**